Guggenheim Upgrades Enliven Therapeutics (NASDAQ:ELVN) to Strong-Buy

Enliven Therapeutics (NASDAQ:ELVN) was upgraded by stock analysts at Guggenheim to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other equities analysts also recently commented on ELVN. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Mizuho raised their target price on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. The Goldman Sachs Group raised their target price on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, May 8th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.17.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $42.30 on Monday. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $48.53. The firm has a market capitalization of $2.58 billion, a P/E ratio of -25.33 and a beta of 0.32. The company’s 50-day moving average is $37.73 and its 200 day moving average is $27.75.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Research analysts anticipate that Enliven Therapeutics will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently modified their holdings of ELVN. KBC Group NV acquired a new position in Enliven Therapeutics during the first quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the 4th quarter valued at approximately $83,000. Finally, Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.